chatgpt Cannabis

WHEN WILL MARIJUANA BE RESCHEDULED? CHAT GPT’S PREDICTION!

by CANNABIS INDUSTRY ACCOUNTING

When will Marijuana be rescheduled? Chat GPT’s Prediction!

Author Chat GPT 06/21/2024

As we stand on the cusp of a historic shift in U.S. drug policy, the potential rescheduling of cannabis from Schedule I to Schedule III is a topic of significant interest and debate. Here, I leverage the power of ChatGPT, an advanced language model developed by OpenAI, to explore the current process, provide an estimated timeline, and predict when this monumental change might occur.

The Power of ChatGPT

ChatGPT is an extraordinary tool designed to assist with a wide range of tasks, from generating text to answering complex questions. It harnesses the power of deep learning to understand and generate human-like text based on the input it receives. As the author of this blog post, ChatGPT has delved into various sources, analyzed the data, and provided a comprehensive overview of the cannabis rescheduling process. This cutting-edge technology enables us to stay informed and make educated predictions about significant regulatory changes.

The Rescheduling Process

The process to reschedule cannabis officially began on May 16, 2024, when the Attorney General submitted a notice of proposed rulemaking to the Federal Register. This initiated a formal rulemaking process involving several key steps:

Public Comment Period: Once the proposed rule is published, there is a 60-day public comment period during which stakeholders and the general public can submit their opinions and evidence. This period is crucial for gathering diverse perspectives on the proposed change (JD Supra) (Home | Holland & Knight) (Marijuana Moment).

Administrative Hearings: Following the comment period, the DEA may hold administrative hearings if requested by interested parties. These hearings are similar to federal bench trials, involving expert testimonies and detailed reviews of the evidence presented. This phase can significantly extend the timeline, often taking several months (JD Supra) (Marijuana Moment).

Review and Final Rule: After the hearings, the DEA will review all comments and evidence before drafting the final rule. This draft must then be reviewed by the Office of Management and Budget (OMB) and submitted to Congress for a 60-day review period, as required for major rules. This step ensures that the rule undergoes thorough scrutiny before implementation (JD Supra) (Marijuana Moment).

Implementation: Assuming no significant delays or objections, the final rule can be implemented after the Congressional review period. Historically, rescheduling processes can take anywhere from several months to over a year, depending on the complexity and volume of input received (Justice) (Vicente LLP) (Marijuana Moment).

Potential Timeline

Given the expedited nature of recent political and public interest in cannabis reform, it is possible that the rescheduling process could be completed within a year. However, considering the possibility of administrative hearings and extensive public comments, the timeline might extend beyond this optimistic estimate. Comparisons with previous rescheduling efforts, such as hydrocodone combination products, suggest that a final rule could be in place by the end of the second quarter of 2025 (JD Supra) (Vicente LLP) (Marijuana Moment).

Prediction: Based on the current pace and historical precedents, ChatGPT predicts that the rescheduling of cannabis to Schedule III will be finalized on July 1, 2025.

Current Debates and Challenges

The proposal to reschedule cannabis has faced significant opposition from various former DEA officials and Republican state attorneys general. These groups have requested public hearings, arguing that rescheduling would have far-reaching implications and requires a thorough review. They contend that rescheduling could undermine federal efforts to combat drug trafficking and contribute to increased drug abuse (Marijuana Moment) (Marijuana Moment).

On the other hand, proponents of rescheduling argue that it aligns federal policy with the growing acceptance of cannabis for medical use across many states. They highlight the potential benefits, such as removing barriers to research and allowing cannabis businesses to take standard business deductions, which are currently prohibited under IRS Section 280E (Marijuana Moment) (Marijuana Moment) (Marijuana Moment).

Conclusion

The rescheduling of cannabis to Schedule III marks a pivotal moment in U.S. drug policy, reflecting changing societal attitudes and scientific understanding of cannabis. While the process is complex and faces significant hurdles, the move could ultimately pave the way for more comprehensive cannabis reforms in the future.

As this process unfolds, it is crucial for stakeholders to stay informed and engaged, ensuring that all perspectives are considered in shaping the future of cannabis regulation in the United States.

For more detailed updates and to participate in the public comment process, visit the Federal Register and DEA websites. Stay tuned to platforms like Marijuana Moment for ongoing coverage and analysis of this critical issue.

 
Justin

THE FUTURE OF THE ORDINARY BUSINESS DEDUCTION FOR CANNABIS BUSINESSES

by CANNABIS INDUSTRY ACCOUNTING

 

We recently ran across an article written in May by Joseph A. Peterson, a Senior Attorney at Plunkett Cooney, called Beyond 280E: The Future of the Ordinary Business Deduction for Cannabis Businesses (Here is the link to the article). His article again highlights how 280E has damaged the cannabis business and argues that companies have the constitutional right to claw back their lost deductions. See Justin’s video, which he recorded back in March, for more details (Watch Justin’s video).

Below are the highlights of Joseph’s article. We encourage you to reach out today to verify if you qualify to amend your returns and/or file a protective claim for a refund.

Highlights of Joseph’s Article:

  1. Economic Impact:
    • Medical and recreational cannabis sales could exceed $33.6 billion, with an additional economic impact of $100.8 billion by the end of 2023.
  2. Section 280E Overview:
    • Section 280E disallows tax deductions for ordinary business expenses for businesses involved in “trafficking” controlled substances, including cannabis.
    • Cannabis businesses are only allowed to deduct the Cost of Goods Sold (COGS), leading to significantly higher effective tax rates (up to 70% or higher) compared to other businesses.
  3. Impact on Cannabis Businesses:
    • The restriction of 280E creates financial strain, reducing the ability to reinvest, hire new employees, and expand operations.
    • Efforts to reform 280E include legislative proposals like The Small Business Tax Equity Act and state-level tax relief through decoupling from federal restrictions.
  4. Recent Developments:
    • Two cannabis Multi-State Operators (MSOs), Truelieve and Ascend Wellness Holdings, successfully filed amended returns to claim ordinary business expense deductions previously excluded under 280E.
    • Truelieve received $113 million in tax refunds for the 2019, 2020, and 2021 tax years, and Ascend Wellness Holdings filed for similar refunds for 2020, 2021, and 2022.
    • Both MSOs plan to file 2023 tax returns as normal corporate taxpayers, excluding 280E.
  5. Implications for the Industry:
    • The amended returns by MSOs have set a precedent and sent shockwaves through the cannabis industry.
    • There is anticipation of additional scrutiny and potential litigation from the IRS regarding these refunds.
  6. Recommendations for Cannabis Businesses:
    • Cannabis businesses should consider filing amended protective returns to preserve the ability to claim retroactive refunds if the federal stance on 280E changes.
    • The process involves identifying the basis for the claim, providing sufficient facts, quantifying the refund, meeting filing requirements, and following up after the 280E contingency is resolved.
    • Filing a protective claim can preserve the right to a refund if 280E’s applicability changes.
  7. Legal and Regulatory Context:
    • The U.S. Supreme Court affirmed the federal government’s authority to regulate cannabis under the Commerce Clause.
    • Justice Clarence Thomas and the DOJ have criticized the enforcement of 280E on medical cannabis sales.
    • Businesses should seek specialist advice and monitor legal developments closely.
    •  

We encourage you to contact us today to verify whether you qualify to amend your returns and/or file a protective claim for refund.

A Major Setback for the Psychedelics Industry: FDA Denies Lykos Therapeutics’ MDMA Therapy Approval

BAD NEWS: MAJOR SETBACK FOR THE PSYCHEDELICS INDUSTRY: FDA DENIES MDMA THERAPY

by Psychadelic Therapy

A Major Setback for the Psychedelics Industry: 

FDA Denies Lykos Therapeutics’ MDMA Therapy Approval

 

 

The psychedelics industry has recently faced a significant setback as the U.S. Food and Drug Administration (FDA) denied Lykos Therapeutics’ approval request for MDMA-assisted therapy for PTSD. This decision has cast a shadow on the burgeoning field of psychedelic-assisted therapies, which has been gaining momentum over the past few years.

FDA Denial and Its Implications

Lykos Therapeutics, previously known as MAPS Public Benefit Corporation (MAPS PBC), has been at the forefront of developing MDMA-assisted therapy for PTSD. The company’s New Drug Application (NDA) for midomafetamine capsules was backed by promising results from multiple clinical trials, including the pivotal Phase 3 MAPP1 and MAPP2 studies. These studies demonstrated significant improvements in PTSD symptoms among participants who received the MDMA-assisted therapy compared to those who received a placebo.

However, during the recent meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee, critics expressed serious concerns about the trial data’s reliability and the therapy’s safety profile. Despite the promising trial results, these concerns ultimately led to the FDA’s decision to deny the approval request, marking a major blow to the psychedelics industry’s efforts to gain regulatory acceptance and mainstream credibility.

A Long Road for Psychedelic Research

This denial is particularly disheartening given the decades of research and advocacy by the Multidisciplinary Association for Psychedelic Studies (MAPS). Founded over 40 years ago, MAPS has been a pioneer in psychedelic research, working tirelessly to develop medical, legal, and cultural contexts for the beneficial use of psychedelics. MAPS incubated Lykos Therapeutics with the goal of bringing MDMA-assisted therapy to market as a viable treatment for PTSD.

The recent FDA decision underscores the challenges that the psychedelics industry faces in gaining regulatory approval. Despite extensive research and significant financial investment, the path to acceptance for psychedelic therapies remains fraught with obstacles. This setback highlights the need for continued rigorous research and transparent dialogue with regulatory bodies to address safety and efficacy concerns.

Moving Forward

While the FDA’s decision is a significant setback, it is not the end of the road for Lykos Therapeutics or the broader psychedelics industry. Both MAPS and Lykos remain committed to their mission of advancing psychedelic research and improving mental health treatment options. They will likely need to address the concerns raised by the FDA and continue their research efforts to demonstrate the safety and efficacy of MDMA-assisted therapy.

For more detailed information on the FDA’s decision and its implications, you can read the full article on the Green Market Report here. Additionally, to learn more about the ongoing work of MAPS and Lykos Therapeutics, visit their websites at MAPS and Lykos Therapeutics.

The road ahead may be challenging, but the commitment and dedication of these organizations provide hope for the future of psychedelic-assisted therapies.

References:

A CASE OF STRATEGIC SILENCE: IRS GUIDANCE ON SECTION 471(C) & SECTION 280E

by Accounting TipsBusiness

IRS Guidance on Section 471(c) and Section 280E: A Case of Strategic Silence

In true IRS fashion, the memorandum recently brought to our attention explicitly avoids addressing the application of Section 471(c) in mitigating the impact of Section 280E. Instead, the focus is narrowly placed on what Section 471(a) allows, which, predictably, is not much. For resellers looking for relief under Section 471(c), the IRS’s silence speaks volumes.

 

The Memorandum’s Take on Section 471(a)

The IRS memorandum clarifies the costs that can be capitalized under Section 471(a) for resellers. These include the invoice price of goods (minus trade discounts) and necessary transportation or other charges incurred in acquiring possession of the goods. However, it stops short of offering guidance on Section 471(c), leaving out any discussion on the broader scope of costs that might be capitalized under this section.

 

What the IRS’s Silence Implies

The careful wording of the memorandum implies that if a taxpayer were applying Section 471(c), a different set of rules might apply, allowing for a broader range of costs incurred in purchasing and reselling goods to be included in inventory. This tacit acknowledgment aligns with what many tax professionals have long understood: Section 471(c) can potentially offer significant relief to businesses impacted by Section 280E.

While the memorandum avoids a direct endorsement, its language suggests that those who meet the criteria for Section 471(c) could capitalize more costs, thereby reducing the taxable income affected by Section 280E. This is a crucial insight for businesses in the cannabis industry and other sectors where Section 280E poses substantial tax challenges.

 

The Role of Form 3115 in Changing Accounting Methods

At the end of the memorandum, the IRS mentions the necessity of filing Form 3115 to change accounting methods. This requirement has likely tripped up many taxpayers who have not filed the necessary paperwork to adopt a Section 471(c) position. Filing Form 3115 is essential for obtaining permission from the IRS to change accounting methods, and failing to do so can result in the denial of the benefits associated with Section 471(c).

For those who have successfully navigated this process, the lack of IRS audits or examinations on their Section 471(c) position may be due to the procedural hurdle of Form 3115. This reinforces the importance of adhering to proper procedures when seeking to change accounting methods and capitalize on the potential benefits of Section 471(c).

 

Conclusion

The IRS’s memorandum may not provide explicit guidance on Section 471(c), but its strategic silence and the careful implications within its wording reinforce what many tax professionals already believe: Section 471(c) offers a viable path to mitigate the impact of Section 280E. By ensuring compliance with the necessary procedural requirements, such as filing Form 3115, businesses can better position themselves to capitalize on the benefits of Section 471(c) and potentially reduce their taxable income under Section 280E.

 

Here is the referenced IRS memorandum which supports our aggressive position on a code section IRC 471(c). 

Psycon Las Vegas 2024

PSYCON LAS VEGAS: NAVIGATING TAX CHALLENGES IN THE PSYCHEDELIC INDUSTRY

by Psilocybin Industry Accounting
Taxation Challenges in the Psychedelic Industries

At the recent PsyCon Convention in Las Vegas, Justin Botillier of Calyx CPA based in Medford, Oregon, delivered a critical presentation addressing the intersection of taxation challenges within the cannabis and psychedelics industries. With deep expertise in cannabis taxation, Justin offered insights that are particularly relevant to both sectors, especially regarding IRS Section 280E.

 

Understanding IRS Section 280E and Its Broad Implications

The core of Justin’s presentation centered on IRS Section 280E. Initially implemented during the war on drugs in the early 1980s, Section 280E prohibits businesses involved with Schedule I or II controlled substances from deducting typical business expenses, except for the Cost of Goods Sold (COGS). Justin detailed how this section affects the psychedelics and cannabis businesses, creating significant financial hurdles due to the inability to deduct ordinary business expenses.

 

Insights for the Psychedelics Industry

While he put much focus on cannabis, Justin effectively bridged the conversation to include the psychedelics industry, which faces similar challenges and uncertainties regarding taxation and regulation. As the psychedelics sector continues to evolve, understanding the application of tax laws like 280E becomes crucial for business owners and investors within this space.

 

Strategic Tax Planning for Cannabis and Psychedelics

Bifurcation Strategy

Justin outlined a bifurcation strategy recommended by other professionals working in the psychedelics space to mitigate the tax burden of 280E. By splitting operations into two entities — one for plant-touching activities and another for non-plant-touching activities — businesses can optimize their tax filings.

Single Entity Strategy

For businesses that prefer a unified operational model, Justin discussed the benefits of a single-entity strategy, emphasizing rigorous accounting practices to allocate costs properly and maximize allowable deductions excluded by 280E. This approach requires a solid understanding of IRC Section 471c, which he explained in detail, demonstrating how careful inventory costing can shield a business from excessive tax liabilities.

 

IRC Section 471c: A Tool for Compliance and Optimization

Explaining the nuances of IRC Section 471c, Justin highlighted how this section allows for greater flexibility in accounting for inventory costs, thereby increasing deductible COGS. This is vital for both cannabis and psychedelic businesses seeking to navigate the limitations imposed by 280E effectively.

 

Anticipating Future Legal and Regulatory Shifts

Justin speculated on potential shifts in drug policy and legal frameworks that could impact the application of 280E to both cannabis and psychedelic businesses. He discussed possible rescheduling efforts and new regulatory developments, suggesting that changes in the legal landscape could mitigate some of the current challenges faced under 280E, beyond just rescheduling cannabis.

 

Expert Guidance for Navigating Complex Tax Landscapes

Concluding his presentation at PsyCon, Justin Botillier emphasized the importance of engaging with tax professionals who specialize in cannabis and, increasingly, in psychedelics. As the regulatory environments evolve, his insights into effective tax planning provide a roadmap for businesses to navigate these complex fields while maintaining compliance and optimizing financial outcomes.


Justin warns that beyond concerns about the ramifications of IRS audits, companies operating in “trafficking” businesses need to be extremely careful about whom they choose to file tax returns. More often than not, it is the accountant who will mire their clients in tax debt rather than the IRS.

ContactUs

Simply fill out the form and we will be in touch to answer any of your queries, 

And feel free to check out our blog & video Section for more info.

DEA Cannabis Rescheduling - Calyx CPA

“IS THE DEA’S RESPONSE TO RESCHEDULING CANNABIS OVERLY HYPED?” CALYX RESPONDS……

by CANNABIS INDUSTRY ACCOUNTINGUncategorised

 

Cannabis Rescheduling and the IRS’s Response to Business Deductions

The recent decision by the Drug Enforcement Administration (DEA) to consider rescheduling marijuana under the Controlled Substances Act (CSA) marks a watershed moment in the history of American drug policy. Initially classified as a Schedule I drug, marijuana was deemed to have no medical value and a high potential for abuse, placing it alongside substances like heroin and LSD. This strict classification has governed its legal status, restricting not only its use but also research into its potential benefits.

The push for rescheduling comes on the heels of a comprehensive review by the U.S. Department of Health and Human Services (HHS), which highlighted marijuana’s accepted medical use and lower abuse potential relative to other Schedule I drugs. The proposal to shift marijuana to Schedule III, which includes drugs like ketamine and some anabolic steroids, suggests a significant change in federal perspective, recognizing both medical value and a lower risk of dependency.

For businesses in the cannabis industry, this reclassification could open up several financial opportunities, particularly regarding taxation. Currently, under IRS code 280E, cannabis businesses are unable to deduct ordinary business expenses because marijuana is classified as a Schedule I substance. The move to Schedule III would alleviate this issue, allowing these businesses to claim deductions that were previously disallowed. This could significantly reduce their tax burden, making operations potentially more profitable and sustainable.

The process of rescheduling marijuana from Schedule I to Schedule III may take longer than the media portrays. Initially, the proposal must pass through the scrutiny of the White House Office of Management and Budget (OMB), a step that ensures all legal and policy implications are thoroughly evaluated. This review can vary in length but is critical in shaping the framework under which marijuana would be regulated going forward.

Following the OMB review, the proposal enters a public comment period, where stakeholders from various sectors—medical, legal, business, and the general public—can provide feedback. This stage is vital for incorporating community and expert opinions and typically lasts several months, further extending the timeline.

Once the public comment period concludes, the DEA reviews the feedback and makes any necessary adjustments to the proposal. This step can also be time-consuming, as it may require additional rounds of revision and approval to address complex issues raised during the public comments.

The final rule is then published in the Federal Register, formalizing the rescheduling of marijuana. This publication is the trigger for the IRS to begin adjusting its policies, including the re-evaluation of tax codes such as 280E, which currently prevents cannabis businesses from deducting typical business expenses.

The IRS will likely respond by issuing new guidelines and possibly updating forms and instructions to accommodate the changes in marijuana’s scheduling. However, these adjustments won’t be instantaneous and will require time to implement. The IRS must ensure that their systems, procedures, and publications reflect these changes accurately, a process that could extend over several months post-rescheduling.

Throughout this period, businesses must stay informed and prepared for changes in compliance requirements, both from a scheduling and taxation perspective. It’s important to note that while the IRS adjustments will provide future relief, they will not apply retroactively to previous tax years before the reclassification is officially in effect. 

It is vital that you act now. As cannabis businesses anticipate the shift from Schedule I to Schedule III, it goes without saying that good advice is essential to effectively navigate the new regulatory landscape, while poor advice can result in permanent harm to your business.

Recognizing that the IRS will not allow retroactive application of tax deductions, minimally businesses should consider filing protective claims for refund to preserve the right to amend past returns based on the outcome of future legal changes. Additionally, firms like Calyx CPA are confident that the CSA’s application to states with cannabis programs will eventually be overturned. Following the example of companies like Trulieve, which received $113 million in refunds from amending their tax returns, they encourage cannabis businesses to maintain meticulous records and consider filing amended returns where feasible. They advocate for a proactive approach in managing audits and potential disputes with the IRS, emphasizing the necessity of sound legal arguments and rigorous compliance with emerging regulations.

 

 

Secure Your Refund Form

Join our next live Q&A

Cannabis Tax Refunds

INSIGHTS ON AMENDING RETURNS & NAVIGATING LEGAL CHANGES

by Accounting TipsCANNABIS INDUSTRY ACCOUNTING

Insights on Amending Returns and Navigating Legal Changes

Join Justin Botillier and Jamie Jorgenstone as they delve into the complexities of amending tax returns in the cannabis industry. This timely webinar comes as cannabis businesses look to amend their returns for refunds impacted by the infamous Section 280E of the tax code. The session shines a light on the potential rescheduling of cannabis and explores the constitutionality of the Controlled Substances Act in state-regulated markets.

Justin and Jamie provide expert analysis on how past court decisions and the current legal landscape could impact your business’s ability to reclaim lost deductions. They discuss the critical aspect of managing audits and leveraging legal precedents effectively. The webinar is an essential resource for cannabis business owners and legal professionals seeking to optimize their tax strategies and maximize potential refunds.

Don’t miss this opportunity to gain invaluable insights from experienced professionals on navigating the evolving tax rules affecting the cannabis industry. Whether you’re refining your approach to tax liabilities or exploring ways to challenge unjust fiscal policies, this session offers practical advice and strategic perspectives.

 

Secure Your Refund Form

Join our next live Q&A

Psychedelics Oregon

CALIFORNIA’S PIONEERING LEGISLATION FOR PSYCHEDELIC THERAPY

by Psilocybin Industry AccountingUncategorised

California’s Pioneering Legislation for Psychedelic Therapy

In an era where mental health innovation is more crucial than ever, California stands at the forefront of a transformative shift. The recent passage of Senate Bill 1012, introduced by Sen. Scott Wiener, marks a significant development in the use of psychedelics for therapeutic purposes. Here’s a deep dive into what this groundbreaking legislation entails and its potential ripple effects, particularly for states like Oregon.

A New Dawn for Psychedelic Therapy

Under SB 1012, California is set to establish regulated service centers where adults aged 21 and older can access substances such as psilocybin, MDMA, mescaline, and DMT in a professionally supervised setting. This initiative, aptly named the “Regulated Therapeutic Access to Psychedelics Act,” is not merely about accessibility but is structured to ensure safety and efficacy through stringent oversight (Marijuana Moment).

The Framework of Regulation

The proposed service centers will operate under the aegis of the newly formed Division of Regulated Psychedelic Substances Control within the California Department of Consumer Affairs. This division will oversee the training and licensing of facilitators who must hold medical licenses, thereby ensuring that participants are in capable hands. This regulatory mechanism aims to foster a safe environment for those exploring psychedelic therapies as avenues for profound healing (KQED).

Health Safeguards and Accessibility

Participants in the program will undergo thorough health and safety screenings to tailor their experiences safely. The bill interestingly does not limit access to individuals with predefined medical conditions, broadening the potential benefits to a wider audience. It also emphasizes the importance of follow-up care, which includes integration services to help individuals process their experiences meaningfully (The Marijuana Herald).

The Broader Implications

Proponents of the bill argue that psychedelics hold immense potential in treating conditions resistant to conventional treatments, such as severe depression and PTSD. This legislation comes in response to Governor Gavin Newsom’s earlier veto of a more extensive decriminalization bill, signaling a cautious but progressive approach towards psychedelic therapy. The governor’s guidance has shaped this legislation to focus more narrowly on therapeutic use, ensuring that it’s paired with appropriate safety protocols (Marijuana Moment).

What This Means for Oregon and Beyond

California’s legislative advancements serve as a potential blueprint for other states, including Oregon, which has shown interest in similar reforms. The Oregon community, particularly businesses and healthcare providers, should closely monitor California’s rollout and outcomes to adapt and prepare for possible legislative shifts in their state. This movement isn’t just about changing laws but is a part of a larger shift towards integrating more holistic and progressive treatments into mental health care (DoubleBlind Mag).

As this bill progresses through further legislative stages, it will be crucial to watch how it influences not only the landscape of mental health treatment in California but also sets a precedent for other states considering similar pathways. For professionals and businesses in the cannabis and psychedelic sectors in Oregon, staying informed and prepared is key to navigating the potential changes that might come with such legislative models.

In essence, California’s move towards regulated psychedelic therapy is a beacon of innovation in mental health care, providing a glimpse into a future where these powerful substances are harnessed safely and effectively to heal and transform lives.

SOFF

SOUTHERN OREGON FAMILY FARMS CO-OP

by Accounting TipsCANNABIS INDUSTRY ACCOUNTING

Justin Botillier, the CEO of Calyx CPA in Medford, Oregon, shares his insights and personal journey within the cannabis industry. His commitment to cannabis legalization began with his high school senior project, and has since evolved into a professional and passionate advocacy.

Calyx CPA, under Justin’s leadership, is dedicated to serving the cannabis industry, mirroring his commitment to justice and community support. He points to Southern Oregon as a historic hub for cannabis cultivation, with Southern Oregon Family Farms (SOFF) leading the charge. 

This region is celebrated for its deep-rooted knowledge, sustainable farming techniques, and the high efficacy of its cannabis products, making them some of the finest on the global stage. 

SOFF is particularly noted for its commitment to environmentally friendly outdoor cultivation, which utilizes natural resources like sunlight and soil. This method not only minimizes the environmental footprint but also highlights the unique advantages Southern Oregon offers over other regions.

Despite the flourishing industry, Justin underscores the significant challenges it faces, such as bureaucratic obstacles and widespread misinformation among consumers. These threats undermine the sustainability and growth of local cannabis farms.

Justin calls for robust community engagement and support for the industry’s mission. He emphasizes that backing this cause is more than just community investment; it’s an investment in the collective future. Such support is vital for the cannabis industry in Southern Oregon to thrive, ensuring it remains sustainable and prosperous for generations to come.

 

 

ContactUs

Simply fill out the form and we will be in touch to answer any of your queries, 

And feel free to check out our blog & video Section for more info.

INTERVIEWING BRITT ROLLINS, CEO OF THE NATIONAL PSYCHEDELICS ASSOCIATION

by Psilocybin Industry Accounting

Navigating the Psychedelics Industry: How the National Psychedelics Association is Pioneering Change

The Psychedelics Industry, once a fringe sector, has rapidly evolved into a significant area of interest for both investors and healthcare professionals alike. At the forefront of this burgeoning industry is the National Psychedelics Association (NPA), a pioneering body dedicated to facilitating the growth and regulatory navigation of psychedelic-related businesses. The NPA plays a crucial role in addressing both the opportunities and challenges encountered by those within this space, particularly in relation to financial services, business solutions, and legislative advocacy. This article delves into the comprehensive efforts of the NPA to support the psychedelics community and foster an environment conducive to the sector’s sustainable development.

Introduction to the National Psychedelics Association

The National Psychedelics Association (NPA), established with the vision of supporting the evolving needs of the psychedelics industry, serves as a beacon for those navigating the complex landscape of psychedelic substances. With a focus on promoting safe, ethical, and legal access, the NPA provides invaluable resources, including regulatory guidance, business support, and educational services. As the industry burgeons, the association’s role in uniting businesses, researchers, and enthusiasts becomes increasingly vital, ensuring the psychedelic movement progresses with integrity and professionalism.

Challenges with Banking and Financial Services

One of the most pressing obstacles faced by businesses within the psychedelics industry is the limited access to banking and financial services. Given the legal ambiguities and evolving regulations surrounding psychedelics, many financial institutions are hesitant to engage with businesses in this sector. This hesitancy can stifle growth, limiting companies’ abilities to secure funding, process payments, and manage operations efficiently. Recognizing these challenges, the NPA actively works with stakeholders to bridge the gap, advocating for clearer regulations and fostering relationships with financial institutions open to supporting the industry.

Efforts to Provide Business Solutions

In response to the unique demands of the psychedelics market, the National Psychedelics Association has embarked on a mission to deliver targeted business solutions. These efforts include offering strategic advice, facilitating networking opportunities, and providing insights into best practices for navigating the market. Furthermore, the NPA is instrumental in advocating for changes that could alleviate some of the financial and operational burdens on businesses, aiming to cultivate a thriving and competitive industry landscape.

Support for Service Centers

Service centers, such as therapeutic clinics and research facilities, constitute a critical component of the psychedelics ecosystem. The NPA recognizes the challenges such establishments face, from regulatory hurdles to logistical complexities. To address these issues, the association offers tailored support encompassing regulatory compliance, staff education, and community-building initiatives. This comprehensive approach ensures that service centers can deliver their invaluable services effectively and within legal bounds.

Guidance for Industry Professionals

The evolving landscape of the psychedelics industry necessitates continuous learning and adaptation by its professionals. The National Psychedelics Association acknowledges this need by providing a plethora of educational resources, workshops, and seminars geared towards enhancing the knowledge and skills of industry participants. By equipping professionals with the latest information on legislation, research, and market trends, the NPA empowers individuals to navigate the industry with confidence and contribute positively to its development. In conclusion, the National Psychedelics Association stands at the vanguard of the psychedelics movement, tirelessly working to address the sector’s multifaceted challenges while promoting growth and innovation. Through its comprehensive support services and advocacy efforts, the NPA is pioneering change, laying the groundwork for a future where the psychedelics industry flourishes, benefiting individuals and society at large.